Table 1 Summary of baseline characteristics
Characteristic | Masitinib treatment (n= 26) | Placebo (n= 8) | P value |
|---|---|---|---|
Age (years) | 72 ± 12 | 78 ± 11 | 0.167 |
Gender (male/female) | 11 (42%)/15 (58%) | 2 (25%)/6 (75%) | 0.444 |
Time since diagnosis (years) | 1.7 ± 1.1 | 1.8 ± 0.8 | 0.320 |
ADAS-Cog (0 to 70) | 18.8 ± 6.7 | 25.6 ± 12.1 | 0.161 |
MMSE (0 to 30) | 19.1 ± 3.9 | 18.0 ± 4.4 | 0.650 |
CDR (1/2) | 21 (81%)/5 (19%) | 6 (75%)/2 (25%) | 1.000 |
ADCS-ADL (0 to 70) | 47.1 ± 11.2 | 45.9 ± 18.0 | 0.850 |
Concomitant Alzheimer's treatment | |||
Cholinesterase inhibitors | 26 (100%) | 8 (100%) | 0.180 |
Memantine | 4 (15%) | 2 (25%) | 0.610 |